Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissière F, Laurent-Puig P, Ychou M, Mazard T. Samalin E, et al. Among authors: mazard t. Br J Cancer. 2014 Mar 4;110(5):1148-54. doi: 10.1038/bjc.2013.813. Epub 2014 Jan 9. Br J Cancer. 2014. PMID: 24407191 Free PMC article. Clinical Trial.
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T, Ychou M, Thezenas S, Poujol S, Pinguet F, Thirion A, Bleuse JP, Portales F, Samalin E, Assenat E. Mazard T, et al. Cancer Chemother Pharmacol. 2012 Mar;69(3):807-14. doi: 10.1007/s00280-011-1764-z. Epub 2011 Oct 30. Cancer Chemother Pharmacol. 2012. PMID: 22037922 Clinical Trial.
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
Assenat E, Mineur L, Mollevi C, Lopez-Crapez E, Lombard-Bohas C, Samalin E, Portales F, Walter T, de Forges H, Dupuy M, Boissière-Michot F, Ho-Pun-Cheung A, Ychou M, Mazard T. Assenat E, et al. Among authors: mazard t. Int J Cancer. 2021 Feb 1;148(3):682-691. doi: 10.1002/ijc.33225. Epub 2020 Sep 2. Int J Cancer. 2021. PMID: 33405269 Clinical Trial.
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Assenat E, de la Fouchardière C, Portales F, Ychou M, Debourdeau A, Desseigne F, Iltache S, Fiess C, Mollevi C, Mazard T. Assenat E, et al. Among authors: mazard t. ESMO Open. 2021 Dec;6(6):100318. doi: 10.1016/j.esmoop.2021.100318. Epub 2021 Nov 24. ESMO Open. 2021. PMID: 34837745 Free PMC article. Clinical Trial.
Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study.
Alouani E, Mercier M, Flecchia C, Auclin E, Hollebecque A, Mazard T, Turpin A, Pernot S, Cohen R, Dutherage M, Kim S, Sclafani F, Ben-Abdelghani M, Herve C, Aparicio T, De La Fouchardière C, Perkins G, Hautefeuille V, Jaffrelot M, Gallois C, Bongard V, Tougeron D, Taïeb J, Guimbaud R. Alouani E, et al. Among authors: mazard t. ESMO Open. 2023 Jun;8(3):101574. doi: 10.1016/j.esmoop.2023.101574. Epub 2023 May 25. ESMO Open. 2023. PMID: 37244250 Free PMC article.
Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study.
Martinelli E, Cremolini C, Mazard T, Vidal J, Virchow I, Tougeron D, Cuyle PJ, Chibaudel B, Kim S, Ghanem I, Asselain B, Castagné C, Zkik A, Khan S, Arnold D. Martinelli E, et al. Among authors: mazard t. ESMO Open. 2022 Dec;7(6):100603. doi: 10.1016/j.esmoop.2022.100603. Epub 2022 Nov 8. ESMO Open. 2022. PMID: 36368253 Free PMC article.
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer.
Mirandola A, Kudriavtsev A, Cofre Muñoz CI, Navarro RC, Macagno M, Daoud S, Sanchez C, Pastor B, Pisareva E, Marin MS, Ruiz JG, Piris A, Rodriguez AG, Gonzalez NS, Vivancos A, Quarà V, Mellano A, Borghi F, Corti G, Marchiò C, Sapino A, Bartolini A, Crisafulli G, Bardelli A, Di Maio M, Lossaint G, Frayssinoux F, Crapez E, Ychou M, Soler RS, Fenocchio E, Fernandez Calotti PX, Mazard T, Vivas CS, Elez E, Di Nicolantonio F, Thierry AR. Mirandola A, et al. Among authors: mazard t. EBioMedicine. 2024 Sep 19;108:105352. doi: 10.1016/j.ebiom.2024.105352. Online ahead of print. EBioMedicine. 2024. PMID: 39303668
Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.
Gallois C, Bergen ES, Auclin É, Pernot S, Higué J, Trouilloud I, Touchefeu Y, Turpin A, Mazard T, Sartore-Bianchi A, Prenen H, Alberti A, Pilla L, Cuissy S, Wookey V, Perret A, Melchior C, Artru P, Dubreuil O, Drouillard A, Doat S, Lavolé J, Basile D, Perkins G, Jary M, Stintzing S, Jos J, Tougeron D, Taieb J. Gallois C, et al. Among authors: mazard t. ESMO Open. 2024 Sep 9;9(9):103696. doi: 10.1016/j.esmoop.2024.103696. Online ahead of print. ESMO Open. 2024. PMID: 39255538 Free PMC article.
Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?
de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prévostel C. de Pellegars-Malhortie A, et al. Among authors: mazard t. Pharmaceuticals (Basel). 2024 Jul 16;17(7):949. doi: 10.3390/ph17070949. Pharmaceuticals (Basel). 2024. PMID: 39065798 Free PMC article. Review.
87 results